Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (18)

2024

  1. Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study

    Open Forum Infectious Diseases, Vol. 11, Núm. 1

2021

  1. Corrigendum: Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro (Front. Immunol, (2020), 11, (565924), 10.3389/fimmu.2020.565924)

    Frontiers in Immunology

  2. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

    The Lancet HIV, Vol. 8, Núm. 11, pp. e668-e678

2020

  1. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

    AIDS and Behavior, Vol. 24, Núm. 12, pp. 3533-3544

2019

  1. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 12, pp. 2474-2481

2018

  1. Authors’ response to correspondence for EPI-STREP-064 publication

    European Journal of Pediatrics

  2. Bacteria from bronchoalveolar lavage fluid from children with suspected chronic lower respiratory tract infection: results from a multi-center, cross-sectional study in Spain

    European Journal of Pediatrics, Vol. 177, Núm. 2, pp. 181-192

2017

  1. Addressing unmet needs in understanding asthma mechanisms

    European Respiratory Journal, Vol. 49, Núm. 5

  2. Asthma research in Europe: A transformative agenda for innovation and competitiveness

    European Respiratory Journal, Vol. 49, Núm. 5

2016

  1. Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument

    Clinical and Experimental Allergy

  2. Sorting the good from the bad: The different approaches to predict cognitive properties of new symptomatic drug candidates for neurodegenerative diseases in early development

    CNS and Neurological Disorders - Drug Targets

2015

  1. Cognitive Impairment After Sleep Deprivation Rescued by Transcranial Magnetic Stimulation Application in Octodon degus

    Neurotoxicity Research, Vol. 28, Núm. 4, pp. 361-371

  2. Transcranial magnetic stimulation and aging: Effects on spatial learning and memory after sleep deprivation in Octodon degus

    Neurobiology of Learning and Memory, Vol. 125, pp. 274-281

2014

  1. Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus

    Neuropharmacology, Vol. 85, pp. 206-214

2013

  1. Effects of pharmacological agents, sleep deprivation, Hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: Towards translational challenge models for drug discovery in Alzheimer's disease

    Clinical Neurophysiology, Vol. 124, Núm. 3, pp. 437-451

  2. Evaluation of symptomatic drug effects in Alzheimer's disease: Strategies for prediction of efficacy in humans

    Drug Discovery Today: Technologies, Vol. 10, Núm. 3

  3. Octodon degus: A model for the cognitive impairment associated with alzheimer's disease

    CNS Neuroscience and Therapeutics, Vol. 19, Núm. 9, pp. 643-648

1994

  1. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis

    EMBO Journal, Vol. 13, Núm. 24, pp. 5818-5825